Hyperhidrosis Treatment Market By Type (Axillary hyperhidrosis, Palmar hyperhidrosis, Plantar hyperhidrosis, Others), By Treatment (Botulinum toxin injections, Topical treatment, Oral medication), By Age (Below 50 years, Above 50 years): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global hyperhidrosis treatment market was valued at $575.3 million in 2021, and is estimated to reach $ 950.7 million by 2031, growing at a CAGR of 5.1% from 2022 to 2031.
A person with hyperhidrosis experiences excessive and unpredictable sweating. When cool or when they are at rest, people with hyperhidrosis may nevertheless perspire. A person’s body's sweat glands overreact in hyperhidrosis. Excessive sweating can occasionally be brought on by a health issue or emotion (such as anxiety). Controlling the symptoms of hyperhidrosis can be a constant struggle for many people. Hyperhidrosis patients seem to have excessively active sweat glands. Uncontrollable sweating can cause severe physical and emotional distress. The cause of hyperhidrosis is unidentified and it is generally believed to be the result of a disturbance with the portion of the nervous system that regulates sweating. The impact of hyperhidrosis symptoms on life can vary greatly in terms of their severity.
The major factors that drive the growth of the hyperhidrosis treatment market are rise in incidence of hyperhidrosis and surge in product launch & product approval are the factors attributed to the growth of the hyperhidrosis treatment market. In addition, upsurge in utilization of topical treatments is a key trend of the market, which is expected to fuel the market growth during the forecast period.Significant surge in the incidence of hyperhidrosis is one leading factor for the growth of the market. Estimates suggest between 2% and 5% of people in the U.S. have hyperhidrosis Thus, such high number of cases are expected to boost the hyperhidrosis treatment procedures.
In addition, rise in product launch drives the market growth, for instance, in June 2022, Dr August Wolff GmbH & Co. Kg Drugs presented the new drug Axhidrox. It is topical treatment for severe primary axillary hyperhidrosis in adults. However, lack of awareness about treatment scenario is expected to hinder the growth of the market. Conversely, increasing consumer demands in developing countries is expected to provide a great opportunity for the investors to invest in the market.
The hyperhidrosis treatment market is segmented on the basis of type, treatment, age, and region. On the basis of type, the market is categorized into axillary hyperhidrosis palmar hyperhidrosis, plantar hyperhidrosis, and others. By treatment, it is divided into botulinum toxin injection, topical treatment, and oral medication. Oral medication is further bifurcated into anticholinergics and others. By age, it is classified into below 50 years and above 50 years. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
The major players profiled in the report are AbbVie Inc, Avanor Healthcare Ltd , Brickbell Biotech, Inc , Dr August Wolff GmbH & Co. Kg Drugs, Dr. Reddy's Laboratories Ltd, Eirion Therapeutics, Inc, Eli Lilly and Company, Hugel, Inc., Kaken Pharmaceutical Co., Ltd, Intas Pharmaceuticals Ltd, Roivant Sciences Ltd., and Theravida, Inc.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hyperhidrosis treatment market analysis from 2021 to 2031 to identify the prevailing hyperhidrosis treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the hyperhidrosis treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global hyperhidrosis treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
Axillary hyperhidrosis
Palmar hyperhidrosis
Plantar hyperhidrosis
Others
By Treatment
Botulinum toxin injections
Topical treatment
Oral medication
Type
Anticholinergics
Others
By Age
Below 50 years
Above 50 years
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest Of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest Of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest Of LAMEA
Key Market Players
AbbVie Inc.
Avanor Healthcare Ltd
Brickbell Biotech, Inc
Dr August Wolff Gmbh & Co. Kg Drugs
Eirion Therapeutics, Inc
Eli Lilly and Company
Hugel, Inc
Kaken Pharmaceutical Co., Ltd.
Roivant Sciences Ltd.
Theravida, Inc
Dr. Reddy's Laboratories Ltd.
Intas Pharmaceuticals Ltd
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- 3.7.Patent Landscape
- CHAPTER 4: HYPERHIDROSIS TREATMENT MARKET, BY TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Axillary hyperhidrosis
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Palmar hyperhidrosis
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Plantar hyperhidrosis
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Others
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- CHAPTER 5: HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Botulinum toxin injections
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Topical treatment
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Oral medication
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.4.4 Oral medication Hyperhidrosis Treatment Market by Type
- 5.4.4.1 Anticholinergics Market size and forecast, by region
- 5.4.4.2 Others Market size and forecast, by region
- CHAPTER 6: HYPERHIDROSIS TREATMENT MARKET, BY AGE
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Below 50 years
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Above 50 years
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- CHAPTER 7: HYPERHIDROSIS TREATMENT MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Type
- 7.2.3 North America Market size and forecast, by Treatment
- 7.2.3.1 North America Oral medication Hyperhidrosis Treatment Market by Type
- 7.2.4 North America Market size and forecast, by Age
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Type
- 7.2.5.1.2 Market size and forecast, by Treatment
- 7.2.5.1.3 Market size and forecast, by Age
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Type
- 7.2.5.2.2 Market size and forecast, by Treatment
- 7.2.5.2.3 Market size and forecast, by Age
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Type
- 7.2.5.3.2 Market size and forecast, by Treatment
- 7.2.5.3.3 Market size and forecast, by Age
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Type
- 7.3.3 Europe Market size and forecast, by Treatment
- 7.3.3.1 Europe Oral medication Hyperhidrosis Treatment Market by Type
- 7.3.4 Europe Market size and forecast, by Age
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Type
- 7.3.5.1.2 Market size and forecast, by Treatment
- 7.3.5.1.3 Market size and forecast, by Age
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Type
- 7.3.5.2.2 Market size and forecast, by Treatment
- 7.3.5.2.3 Market size and forecast, by Age
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Type
- 7.3.5.3.2 Market size and forecast, by Treatment
- 7.3.5.3.3 Market size and forecast, by Age
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Type
- 7.3.5.4.2 Market size and forecast, by Treatment
- 7.3.5.4.3 Market size and forecast, by Age
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Type
- 7.3.5.5.2 Market size and forecast, by Treatment
- 7.3.5.5.3 Market size and forecast, by Age
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Type
- 7.3.5.6.2 Market size and forecast, by Treatment
- 7.3.5.6.3 Market size and forecast, by Age
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Treatment
- 7.4.3.1 Asia-Pacific Oral medication Hyperhidrosis Treatment Market by Type
- 7.4.4 Asia-Pacific Market size and forecast, by Age
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Type
- 7.4.5.1.2 Market size and forecast, by Treatment
- 7.4.5.1.3 Market size and forecast, by Age
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Type
- 7.4.5.2.2 Market size and forecast, by Treatment
- 7.4.5.2.3 Market size and forecast, by Age
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Type
- 7.4.5.3.2 Market size and forecast, by Treatment
- 7.4.5.3.3 Market size and forecast, by Age
- 7.4.5.4 Australia
- 7.4.5.4.1 Market size and forecast, by Type
- 7.4.5.4.2 Market size and forecast, by Treatment
- 7.4.5.4.3 Market size and forecast, by Age
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Type
- 7.4.5.5.2 Market size and forecast, by Treatment
- 7.4.5.5.3 Market size and forecast, by Age
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Type
- 7.4.5.6.2 Market size and forecast, by Treatment
- 7.4.5.6.3 Market size and forecast, by Age
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Type
- 7.5.3 LAMEA Market size and forecast, by Treatment
- 7.5.3.1 LAMEA Oral medication Hyperhidrosis Treatment Market by Type
- 7.5.4 LAMEA Market size and forecast, by Age
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Type
- 7.5.5.1.2 Market size and forecast, by Treatment
- 7.5.5.1.3 Market size and forecast, by Age
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Type
- 7.5.5.2.2 Market size and forecast, by Treatment
- 7.5.5.2.3 Market size and forecast, by Age
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Type
- 7.5.5.3.2 Market size and forecast, by Treatment
- 7.5.5.3.3 Market size and forecast, by Age
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Type
- 7.5.5.4.2 Market size and forecast, by Treatment
- 7.5.5.4.3 Market size and forecast, by Age
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 AbbVie Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Avanor Healthcare Ltd
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Brickbell Biotech, Inc
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Dr August Wolff Gmbh & Co. Kg Drugs
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Eirion Therapeutics, Inc
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Eli Lilly and Company
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Hugel, Inc
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Kaken Pharmaceutical Co., Ltd.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Roivant Sciences Ltd.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Theravida, Inc
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 Dr. Reddy's Laboratories Ltd.
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- 9.12 Intas Pharmaceuticals Ltd
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 2. HYPERHIDROSIS TREATMENT MARKET, FOR AXILLARY HYPERHIDROSIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. HYPERHIDROSIS TREATMENT MARKET FOR AXILLARY HYPERHIDROSIS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. HYPERHIDROSIS TREATMENT MARKET, FOR PALMAR HYPERHIDROSIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. HYPERHIDROSIS TREATMENT MARKET FOR PALMAR HYPERHIDROSIS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. HYPERHIDROSIS TREATMENT MARKET, FOR PLANTAR HYPERHIDROSIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. HYPERHIDROSIS TREATMENT MARKET FOR PLANTAR HYPERHIDROSIS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 8. HYPERHIDROSIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. HYPERHIDROSIS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 10. GLOBAL HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 11. HYPERHIDROSIS TREATMENT MARKET, FOR BOTULINUM TOXIN INJECTIONS, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. HYPERHIDROSIS TREATMENT MARKET FOR BOTULINUM TOXIN INJECTIONS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 13. HYPERHIDROSIS TREATMENT MARKET, FOR TOPICAL TREATMENT, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. HYPERHIDROSIS TREATMENT MARKET FOR TOPICAL TREATMENT, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 15. HYPERHIDROSIS TREATMENT MARKET, FOR ORAL MEDICATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. HYPERHIDROSIS TREATMENT MARKET FOR ORAL MEDICATION, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 17. GLOBAL ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 18. HYPERHIDROSIS TREATMENT MARKET, FOR ANTICHOLINERGICS, BY REGION, 2021-2031 ($MILLION)
- TABLE 19. HYPERHIDROSIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 20. GLOBAL HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 21. HYPERHIDROSIS TREATMENT MARKET, FOR BELOW 50 YEARS, BY REGION, 2021-2031 ($MILLION)
- TABLE 22. HYPERHIDROSIS TREATMENT MARKET FOR BELOW 50 YEARS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 23. HYPERHIDROSIS TREATMENT MARKET, FOR ABOVE 50 YEARS, BY REGION, 2021-2031 ($MILLION)
- TABLE 24. HYPERHIDROSIS TREATMENT MARKET FOR ABOVE 50 YEARS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 25. HYPERHIDROSIS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 26. NORTH AMERICA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 27. NORTH AMERICA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 28. NORTH AMERICA ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 29. NORTH AMERICA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 30. NORTH AMERICA HYPERHIDROSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 31. U.S. HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 32. U.S. HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 33. U.S. HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 34. CANADA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 35. CANADA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 36. CANADA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 37. MEXICO HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 38. MEXICO HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 39. MEXICO HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 40. EUROPE HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 41. EUROPE HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 42. EUROPE ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 43. EUROPE HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 44. EUROPE HYPERHIDROSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 45. GERMANY HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 46. GERMANY HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 47. GERMANY HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 48. FRANCE HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 49. FRANCE HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 50. FRANCE HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 51. UK HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 52. UK HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 53. UK HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 54. ITALY HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 55. ITALY HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 56. ITALY HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 57. SPAIN HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 58. SPAIN HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 59. SPAIN HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 60. REST OF EUROPE HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 61. REST OF EUROPE HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 62. REST OF EUROPE HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 63. ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 64. ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 65. ASIA-PACIFIC ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 66. ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 67. ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 68. JAPAN HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 69. JAPAN HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 70. JAPAN HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 71. CHINA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 72. CHINA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 73. CHINA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 74. INDIA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 75. INDIA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 76. INDIA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 77. AUSTRALIA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 78. AUSTRALIA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 79. AUSTRALIA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 80. SOUTH KOREA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 81. SOUTH KOREA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 82. SOUTH KOREA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 83. REST OF ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 84. REST OF ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 85. REST OF ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 86. LAMEA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 87. LAMEA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 88. LAMEA ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 89. LAMEA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 90. LAMEA HYPERHIDROSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 91. BRAZIL HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 92. BRAZIL HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 93. BRAZIL HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 94. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 95. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 96. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 97. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 98. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 99. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 100. REST OF LAMEA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 101. REST OF LAMEA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 102. REST OF LAMEA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
- TABLE 103.ABBVIE INC.: COMPANY SNAPSHOT
- TABLE 104.ABBVIE INC.: OPERATING SEGMENTS
- TABLE 105.ABBVIE INC.: PRODUCT PORTFOLIO
- TABLE 106.ABBVIE INC.: NET SALES,
- TABLE 107.ABBVIE INC.: KEY STRATERGIES
- TABLE 108.AVANOR HEALTHCARE LTD: COMPANY SNAPSHOT
- TABLE 109.AVANOR HEALTHCARE LTD: OPERATING SEGMENTS
- TABLE 110.AVANOR HEALTHCARE LTD: PRODUCT PORTFOLIO
- TABLE 111.AVANOR HEALTHCARE LTD: NET SALES,
- TABLE 112.AVANOR HEALTHCARE LTD: KEY STRATERGIES
- TABLE 113.BRICKBELL BIOTECH, INC: COMPANY SNAPSHOT
- TABLE 114.BRICKBELL BIOTECH, INC: OPERATING SEGMENTS
- TABLE 115.BRICKBELL BIOTECH, INC: PRODUCT PORTFOLIO
- TABLE 116.BRICKBELL BIOTECH, INC: NET SALES,
- TABLE 117.BRICKBELL BIOTECH, INC: KEY STRATERGIES
- TABLE 118.DR AUGUST WOLFF GMBH & CO. KG DRUGS: COMPANY SNAPSHOT
- TABLE 119.DR AUGUST WOLFF GMBH & CO. KG DRUGS: OPERATING SEGMENTS
- TABLE 120.DR AUGUST WOLFF GMBH & CO. KG DRUGS: PRODUCT PORTFOLIO
- TABLE 121.DR AUGUST WOLFF GMBH & CO. KG DRUGS: NET SALES,
- TABLE 122.DR AUGUST WOLFF GMBH & CO. KG DRUGS: KEY STRATERGIES
- TABLE 123.EIRION THERAPEUTICS, INC: COMPANY SNAPSHOT
- TABLE 124.EIRION THERAPEUTICS, INC: OPERATING SEGMENTS
- TABLE 125.EIRION THERAPEUTICS, INC: PRODUCT PORTFOLIO
- TABLE 126.EIRION THERAPEUTICS, INC: NET SALES,
- TABLE 127.EIRION THERAPEUTICS, INC: KEY STRATERGIES
- TABLE 128.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
- TABLE 129.ELI LILLY AND COMPANY: OPERATING SEGMENTS
- TABLE 130.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
- TABLE 131.ELI LILLY AND COMPANY: NET SALES,
- TABLE 132.ELI LILLY AND COMPANY: KEY STRATERGIES
- TABLE 133.HUGEL, INC: COMPANY SNAPSHOT
- TABLE 134.HUGEL, INC: OPERATING SEGMENTS
- TABLE 135.HUGEL, INC: PRODUCT PORTFOLIO
- TABLE 136.HUGEL, INC: NET SALES,
- TABLE 137.HUGEL, INC: KEY STRATERGIES
- TABLE 138.KAKEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
- TABLE 139.KAKEN PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
- TABLE 140.KAKEN PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
- TABLE 141.KAKEN PHARMACEUTICAL CO., LTD.: NET SALES,
- TABLE 142.KAKEN PHARMACEUTICAL CO., LTD.: KEY STRATERGIES
- TABLE 143.ROIVANT SCIENCES LTD.: COMPANY SNAPSHOT
- TABLE 144.ROIVANT SCIENCES LTD.: OPERATING SEGMENTS
- TABLE 145.ROIVANT SCIENCES LTD.: PRODUCT PORTFOLIO
- TABLE 146.ROIVANT SCIENCES LTD.: NET SALES,
- TABLE 147.ROIVANT SCIENCES LTD.: KEY STRATERGIES
- TABLE 148.THERAVIDA, INC: COMPANY SNAPSHOT
- TABLE 149.THERAVIDA, INC: OPERATING SEGMENTS
- TABLE 150.THERAVIDA, INC: PRODUCT PORTFOLIO
- TABLE 151.THERAVIDA, INC: NET SALES,
- TABLE 152.THERAVIDA, INC: KEY STRATERGIES
- TABLE 153.DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
- TABLE 154.DR. REDDY'S LABORATORIES LTD.: OPERATING SEGMENTS
- TABLE 155.DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
- TABLE 156.DR. REDDY'S LABORATORIES LTD.: NET SALES,
- TABLE 157.DR. REDDY'S LABORATORIES LTD.: KEY STRATERGIES
- TABLE 158.INTAS PHARMACEUTICALS LTD: COMPANY SNAPSHOT
- TABLE 159.INTAS PHARMACEUTICALS LTD: OPERATING SEGMENTS
- TABLE 160.INTAS PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
- TABLE 161.INTAS PHARMACEUTICALS LTD: NET SALES,
- TABLE 162.INTAS PHARMACEUTICALS LTD: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.HYPERHIDROSIS TREATMENT MARKET SEGMENTATION
- FIGURE 2.HYPERHIDROSIS TREATMENT MARKET,2021-2031
- FIGURE 3.HYPERHIDROSIS TREATMENT MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.HYPERHIDROSIS TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.PATENT ANALYSIS BY COMPANY
- FIGURE 13.PATENT ANALYSIS BY COUNTRY
- FIGURE 14.HYPERHIDROSIS TREATMENT MARKET,BY TYPE,2021(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF AXILLARY HYPERHIDROSIS HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF PALMAR HYPERHIDROSIS HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF PLANTAR HYPERHIDROSIS HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHERS HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
- FIGURE 19.HYPERHIDROSIS TREATMENT MARKET,BY TREATMENT,2021(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF BOTULINUM TOXIN INJECTIONS HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF TOPICAL TREATMENT HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
- FIGURE 23.HYPERHIDROSIS TREATMENT MARKET,BY AGE,2021(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF BELOW 50 YEARS HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
- FIGURE 25.COMPARATIVE SHARE ANALYSIS OF ABOVE 50 YEARS HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
- FIGURE 26.HYPERHIDROSIS TREATMENT MARKET BY REGION,2021
- FIGURE 27.U.S. HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 28.CANADA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 29.MEXICO HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 30.GERMANY HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 31.FRANCE HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 32.UK HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 33.ITALY HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 34.SPAIN HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 35.REST OF EUROPE HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 36.JAPAN HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 37.CHINA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 38.INDIA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 39.AUSTRALIA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 40.SOUTH KOREA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 41.REST OF ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 42.BRAZIL HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 43.SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 44.SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 45.REST OF LAMEA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 50.COMPETITIVE DASHBOARD
- FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 52.ABBVIE INC..: NET SALES ,($MILLION)
- FIGURE 53.AVANOR HEALTHCARE LTD.: NET SALES ,($MILLION)
- FIGURE 54.BRICKBELL BIOTECH, INC.: NET SALES ,($MILLION)
- FIGURE 55.DR AUGUST WOLFF GMBH & CO. KG DRUGS.: NET SALES ,($MILLION)
- FIGURE 56.EIRION THERAPEUTICS, INC.: NET SALES ,($MILLION)
- FIGURE 57.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
- FIGURE 58.HUGEL, INC.: NET SALES ,($MILLION)
- FIGURE 59.KAKEN PHARMACEUTICAL CO., LTD..: NET SALES ,($MILLION)
- FIGURE 60.ROIVANT SCIENCES LTD..: NET SALES ,($MILLION)
- FIGURE 61.THERAVIDA, INC.: NET SALES ,($MILLION)
- FIGURE 62.DR. REDDY'S LABORATORIES LTD..: NET SALES ,($MILLION)
- FIGURE 63.INTAS PHARMACEUTICALS LTD.: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook